RPG Life Sciences (RPGLIFE) Q2 25/26 earnings summary

Executive summary

• Achieved 17.2% year-over-year growth in domestic formulations for Q2 FY26, outpacing the Indian pharma market's 7.7% growth; H1 growth at 13.5% versus market's 7.4%.

• H1 FY26 revenue grew 3.8% year-over-year to ₹350.6 crore, with domestic formulations driving 71% of sales.

• Unaudited financial results for Q2 and H1 FY26 show continued profitability and growth year-over-year.

• Naprosyn, the largest brand, grew 16% YOY in H1 and is on track to become the first 100 crore brand.

• Immunosuppressant and mAbs portfolios saw double-digit growth, with mAbs up 21% in H1.

Financial highlights

• Q2 FY26 revenue rose 7.6% sequentially to ₹181.7 crore; PAT grew 8.1% to ₹28.5 crore.

• EBITDA margin for H1 FY26 at 24.0%, down from 26.5% in H1 FY25; PAT margin at 15.6%.

• Net profit for Q2 FY26 was ₹3,685 lakhs, with EPS at ₹22.28, and total comprehensive income for H1 FY26 at ₹6,311 lakhs.

• H1 FY26 revenue up 3.8% year-over-year; H1 PAT (excluding exceptionals) at INR 15.6 crore.

• Revenue from operations for Q2 FY26 was ₹18,168 lakhs, up from ₹17,221 lakhs in Q1 FY26 and ₹17,415 lakhs in Q2 FY25.

Outlook and guidance

• API business expected to recover in H2 as plant resumes full operations.

• Strategic focus on portfolio development, mega-brand building, API business growth, digital transformation, and M&A.

• Ongoing capex and plant modernization to support expansion in regulated and emerging markets.

• The company is confident of recovering the net loss from the fire incident through insurance in subsequent quarters.